tradingkey.logo

Clearside Biomedical plunges after filing for Chapter 11 bankruptcy

ReutersNov 24, 2025 3:22 PM

Shares of drug developer Clearside Biomedical CLSD.O slide 68.7% to $0.85

Co files for Chapter 11 bankruptcy protection in a U.S. court, estimates assets in range of $1 mln to $10 mln and liabilities between $50 mln and $100 mln, as per filing

Co reported a loss of $1.14 per share in the quarter ended September 30, lesser than $1.54 per share a year ago

In its quarterly results filing on November 14, co raised going concerns, saying it may not be able to continue without additional funding or strategic transaction

As part of Chapter 11 process, co plans to pursue an auction and sale of assets under Section 363 of U.S. Bankruptcy Code

Co has been exploring a sale, licensing or partnerships to advance its drug pipeline and SCS platform - a drug delivery system - since July

Including session's move, CLSD stock down 94% YTD

Shares on track for lowest level since listing in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI